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Edited by Lukas HuberAbstract The Rac1 GTPase contains a functional nuclear
localization signal (NLS) and destruction box sequence in the
C-terminal polybasic region. It has been postulated that these
two regulatory sequences may function together, enabling Rac1
to participate in nuclear signaling pathways that ultimately tar-
get it for degradation. We have previously shown that the NLS
activity of Rac1 and the Rac1b splice variant is essential for
Wnt pathway activation. In the present study, we demonstrate
that suppression of nuclear Wnt signaling leads to stabilization
of Rac1 protein. In addition, we show that Rac1b may be under
proteasomal regulation. We propose that Rac1 and Rac1b levels
are regulated by being targeted for degradation through a nega-
tive feedback loop initiated by Wnt signaling.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Rac1 is a member of the Rho family of small GTPases, key
molecules in signaling pathways that control actin cytoskeletal
dynamics, cell adhesion, and gene transcription [1]. Similar to
all members of the small GTPases superfamily, Rac1 activity
was traditionally thought to be primarily regulated biochemi-
cally, by cycling between inactive GDP-bound, and active
GTP-bound states. However, recent studies indicate that
Rac1 activity can be regulated by additional mechanisms such
as sub-cellular localization and protein degradation. Con-
served sequences located at its C-terminal polybasic region
(PBR) have been implicated in these functions [2–4].
The PBR is a conserved structural feature that is present in
several Rho GTPase family members. It is comprised of a ser-
ies of lysine and arginine residues and often precedes the C-ter-
minal CAAX motif. The PBR of Rac1 contains a canonical
nuclear localization signal (NLS) sequence (K(K/R)X(K/R)),
that mediates Rac1 nuclear accumulation [3,5,6]. Speciﬁcally,
the Rac1 PBR domain was recently demonstrated to be inte-Abbreviations: D-box, destruction box; DNTCF4, dominant-negative
TCF4; NLS, nuclear localization signal; PBR, polybasic region
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Rac1 and either the GEF SmgGDS or p120-catenin [5]. Hence,
it has been postulated that the NLS may be required for the
nuclear entry of Rac1, when it is associated with other proteins
in complexes that may be too large to passively diﬀuse through
nuclear pores.
The C-terminal sequences of all Rac GTPase isoforms con-
tain a canonical destruction box (D-box) sequence (RXXL),
which usually targets proteins for proteasome-mediated degra-
dation [3]. In agreement, recent studies have demonstrated that
Rac1 is subject to proteasomal degradation. For example,
Rac1 activation of NADPH oxidase results in a negative feed-
back loop that causes ubiquitin-mediated proteolytic degrada-
tion of Rac1, thereby switching oﬀ reactive oxygen species
production in the cell [7]. Rac1 is also subject to ubiquitin-
mediated proteasomal degradation during the early stages of
epithelial cell scattering by causing disassembly of cell–cell
contacts in Madin Darby Canine Kidney (MDCK) cells [2].
Furthermore, mutation of the D-box sequence from RAVL
to AAVA (residues 174–177) signiﬁcantly elevates the protein
levels of Rac1, indicating functionality of the D-box [3].
Intriguingly, a Rac1 mutant protein in which the Rac1 PBR
is replaced with the RhoA PBR sequence which lacks a
NLS, has greater cytoplasmic localization and signiﬁcantly ele-
vated protein levels compared to wild-type (WT) Rac1 [3].
Considered together, it has been postulated that the NLS
sequence in the PBR directs Rac1 to the nucleus, where
Rac1 participates in signaling pathways that ultimately target
it for proteasomal degradation. However, the functions of
Rac1 that are dependent on nuclear localization and may be
susceptible to degradation have yet to be identiﬁed.
Our lab has previously demonstrated a novel function of the
Rac1 PBR in mediating cross-talk with the canonical Wnt sig-
naling pathway in colorectal cancer cells [6]. Dysregulated Wnt
signaling facilitates tumorigenesis through b-catenin, which
aberrantly accumulates in the nucleus and associates with
T-cell factor/lymphoid enhancer factor (TCF/LEF) transcrip-
tion factors and directs expression of genes involved in tumor
progression [8]. We have shown that Rac1 facilitates b-catenin
nuclear accumulation and causes synergistic activation of b-
catenin/TCF-mediated gene transcription, in a PBR-dependent
manner [6]. Mutating the Rac1 PBR by substituting with neu-
tral glutamine residues greatly impedes nuclear localization of
Rac1 but does not compromise Rac1 catalytic activity or cyto-
solic localization [5]. Using this mutant, we have shown a
drastic reduction of PBR-mutated Rac1 in the nucleus of colo-
rectal cancer cells, and also compromised b-catenin nuclearblished by Elsevier B.V. All rights reserved.
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[6]. In addition, we have recently demonstrated that Rac1b,
a splice variant of Rac1 overexpressed in colon and breast tu-
mors, has an intact PBR consensus sequence which behaves
similarly in Wnt pathway regulation [9]. Mutation of the
PBR in Rac1b abolished its nuclear localization as well as its
synergistic eﬀects on Wnt pathway induction and reversed its
eﬀects on suppression of cellular adhesion. Since the NLS
activity of the Rac1 and Rac1b PBR is critical for Wnt path-
way activation, we speculated whether Rac1 stability, also con-
trolled by PBR sequences, may be aﬀected through Rac1’s
involvement in Wnt pathway activation. In the present study,
we demonstrate that stability of Rac1 and Rac1b isoforms is
regulated by a negative feedback loop initiated by Wnt path-
way signal transduction.2. Materials and methods
2.1. Materials
Tissue culture reagents and fetal bovine serum (FBS) were pur-
chased from Invitrogen Life Technologies. Cycloheximide (CHX)
was purchased from SIGMA. Proteasome inhibitor MG-132 was from
Calbiochem. The constructs used in this study were obtained from the
following sources: Myc-tagged WT Rac1 and activated mutant FLAG-
tagged V12Rac1 – Dr. J. Wrana, SLRI, Mount Sinai Hospital, Toron-
to; pTOPFlash and pFOPFlash promoter-luciferase constructs, WT
TCF4, and dominant-negative (DN) TCF4 expression vectors
– Dr. B. Alman, Hospital for Sick Children, Toronto; WT b-catenin
– Dr. L. Attisano – University of Toronto, Canada; FLAG-tagged
Rac1b – Dr. M. Ahmadian, Max-Planck Institute, Germany. WT
and V12Rac1PBRQ were purchased from UMR cDNAResource Cen-
ter (Missouri).
2.2. Cell culture and transfection
Human colorectal cancer cell lines HCT116 and SW480 were cul-
tured in McCoy’s 5A and DMEM, respectively. Human embryonic
kidney 293 cells were maintained in DMEM. All culture media was
supplemented with 10% FBS and cultured at 37 C in a humidiﬁed
atmosphere of 5% CO2. Cells were seeded 24 h before transfection at
a conﬂuency of 80–90%. All transfections were performed using Lipo-
fectAMINE 2000 (Invitrogen), according to manufacturer’s instruc-
tions, and analyzed 24 h later. Total amounts of transfected DNA
were 8 lg per 60-mm dish for biochemical assays or Western blotting
experiments, and 1 lg per well of a 24-well plate for luciferase assays.
When required, the amount of DNA was adjusted with empty vector.
For MG-132 experiments, cells were treated with MG-132 (10 lM) or
vehicle (DMSO) 24 h post-transfection for 4 h. Transfection eﬃcien-
cies for all experiments were 60–70% as judged by transfection with
b-galactosidase plasmid.
2.3. Luciferase assays
Cells were seeded in 24-well plates at a density of 2 · 105 cells per
well. Luciferase promoter constructs (0.1 lg) pTOPFlash or pFOP-
Flash, were co-transfected with an internal control (0.03 lg of pCMV
b-galactosidase), along with combinations of expression vectors, as
indicated in ﬁgure. Luciferase and b-galactosidase activity was mea-
sured using commercially available kits from Promega (Madison,
WI) and Stratagene, respectively. Luminescence was quantitated using
a Berthold 96-well microplate luminometer.
2.4. Cell fractionation, co-immunoprecipitation, and Western blotting
Whole cell lysates as well as cytoplasmic and nuclear extracts were
prepared and detected as previously described [6]. Co-immunoprecipi-
tation experiments were performed using both whole cell and fraction-
ated cytoplasmic and nuclear lysates. The antibodies used in this study
were HRP-conjugated anti-FLAG and anti-hemagglutin (HA)
(SIGMA), monoclonal anti-b-catenin and monoclonal anti-Paxillin
(Transduction Laboratories, BD Biosciences), monoclonal anti-Topo-
isomerase II (Oncogene Research Products), monoclonal Dvl-3 (SantaCruz), and anti-b-actin (Ambion) and anti-b-tubulin (Santa Cruz) as
loading controls.2.5. V12Rac1 stability assays
HCT116 cells were co-transfected with FLAG-tagged V12Rac1 and
either empty vector or DNTCF4 expression vectors for 24 h in 60 mm
dishes. For cycloheximide (CHX) experiments, cells were treated with
vehicle (DMSO) or CHX (20 lM) for indicated time points and then
whole cell lysates were harvested in RIPA buﬀer followed by Western
blotting. For pulse-chase analysis, cells were starved for 30 min by
incubating in DMEMmedium without methionine (DMEM-). A pulse
period of 45 min in DMEM- with [35S] methionine (100 lCi/dish) fol-
lowed by a chase period varying between 0 and 18 h were performed
before the lysis of the cells. Cell lysates were immunoprecipitated with
an anti-FLAG antibody (SIGMA), and analyzed by Western blot and
visualized by autoradiographic ﬁlms. For normalization, following
FLAG immunoprecipitation, each sample was immediately subjected
to immunoprecipitation with b-actin antibody (SIGMA) and analyzed
similarly. Band intensity of FLAG IP was normalized against corre-
sponding b-actin IP band intensity for each sample, before plotting
on graph. Both CHX and pulse-chase experiments were repeated at
least 2–3 independent times. Results are expressed as the means ± S.D.
Group means were compared for the 18 h time-point using the un-
paired Student’s t-test.2.6. RNA isolation and real-time PCR
Total RNA was harvested 24 h after transfection using the RNeasy
mini-kit (Qiagen). Five microgram of total RNA (quantitated using a
spectrophotometer) was subsequently reverse-transcribed using the
Superscript III Reverse Transcriptase reagent for ﬁrst strand cDNA
synthesis (Invitrogen). Quantiﬁcation of Rac1 mRNA was performed
using real-time RT-PCR on the Applied Biosystems 7900HT real-time
PCR system. SYBR Green 1 dye chemistry was used to quantitate
Rac1 mRNA and b-actin house-keeping gene mRNA. The following
Rac1 speciﬁc primers were used: Forward primer 5 0-ATG CAG
GCC ATC AAG TGT GTG-30 and Reverse primer 5 0-CAA CAG
CAG GCA TTT TCT CTT-3 0. Samples were analyzed in triplicate,
and the entire experiment was repeated three independent times.3. Results
3.1. Rac1 functions in the nucleus to stimulate Wnt signaling
We have previously shown that mutating the PBR abolishes
activation of b-catenin/TCF-mediated transcription by consti-
tutively active (V12)Rac1 mutant, implying that Rac1 likely
needs to be present in the nucleus to carry out these functions.
Since both Rac1 and b-catenin are expressed in the nucleus, we
examined their interaction in nuclear lysates of Rac1-transfec-
ted cells. As shown in Fig. 1A, Rac1 co-immunoprecipitated
with b-catenin in nuclear and cytoplasmic extracts harvested
from human embryonic kidney 293 cells. Nuclear localization
of Dishevelled (Dvl), another integral component of Wnt sig-
nal transduction that lays upstream of b-catenin in the cas-
cade, was recently demonstrated to be required for its
function in the canonical Wnt/b-catenin signaling pathway
[10]. Interestingly, we observed Dvl-3 co-immunoprecipitating
with Rac1 in both fractions. Furthermore, it appeared that
both b-catenin and Dvl-3 predominantly formed complexes
with Rac1 in the nuclear fraction, although all three proteins
were robustly expressed in both cytoplasmic and nuclear ex-
tracts (Fig. 1B). We did not observe interaction of native
Rac1 with b-catenin or Dvl-3. This is likely due to the much
lower levels of active GTP-bound Rac1 present in the endoge-
nous pool and which is likely insensitive to detection by Wes-
tern Blotting. The purity of the nuclear and cytoplasmic
fractions was assessed by re-probing the Western blots with
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Fig. 1. Rac1 associates with Wnt components in the nucleus to regulate activation of Wnt target genes. (A) 293 cells were co-transfected with Dvl-3
(4 lg) and myc-tagged Rac1 (4 lg) for 24 h. Whole cell lysates (WCL), cytoplasmic extracts (CE) or nuclear extracts (NE) were immunoprecipitated
(IP) with Dvl-3 or b-catenin antibody, or normal mouse IgG antibody (negative control) plus agarose beads and separated by SDS–PAGE, and
immunoblotted (IB) with indicated antibodies. (B) Ten micrograms of WCL, CE, and NE used in IPs was IB with b-catenin, Dvl-3, or myc
antibodies to conﬁrm expression of ectopically expressed Dvl-3 and myc-tagged Rac1 and endogenous b-catenin in cellular fractions. (C) 293 cells
were transfected with pTOPFlash/pFOPFlash, Dvl-3 (0.2 lg) and either WT Rac1 (0.7 lg) or Rac1PBRQ (0.2, 0.4, 0.7 lg). Luciferase activity is
expressed as total relative light units (RLU) with histograms representing the average + S.E.M. done in triplicate. Data shown are representative for
three independent experiments.
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teins, topoisomerase II and paxillin, respectively.
Having established a physical association between Rac1 and
Dv1-3, we examined if they could functionally interact in Wnt
pathway regulation by measuring b-catenin/TCF-dependent
transcriptional activation. Using the Wnt-responsive TCF re-
porter TOPFlash, together with the mutant reporter FOP-
Flash as a negative control, we found that Rac1 signiﬁcantly
enhanced Dvl-3 mediated activation of TOPﬂash in 293 cells
(Fig. 1C). Furthermore, co-expression of a Rac1 PBR mutant
that is deﬁcient in nuclear localization (Rac1PBRQ) was un-
able to synergize with Dvl-3 to stimulate TOPFlash promoter
activity, emphasizing the necessity of Rac1 nuclear localization
in this process.
3.2. Co-expression of dominant-negative TCF4 leads to
increased protein expression of Rac1
The C-terminal PBR is involved in regulating the stability of
Rac1 protein [2,3]. Since our data demonstrates an essentialrole for the PBR in Rac1-mediated stimulation of b-catenin/
TCF transcription, we speculated that Rac1 protein stability
may also be aﬀected by Wnt signaling. To address this, we
examined the eﬀects of Wnt pathway inhibition on Rac1 pro-
tein expression. We utilized an amino-terminal truncated mu-
tant of TCF4 (DNTCF4), which can eﬀectively block nuclear
Wnt signaling by binding to TCF binding elements in Wnt
responsive promoters in a dominant-negative manner [11]. In
previous work, we have demonstrated that co-expression of
DNTCF4 completely abolishes V12Rac1-mediated induction
of transcription from Wnt target promoters in HCT116 cells,
a colorectal cancer cell line with constitutively active Wnt sig-
naling [6]. Under similar conditions, examination of Rac1 pro-
tein levels revealed that co-expression of V12Rac1 with
DNTCF4 resulted in a striking dose-dependent increase in
V12Rac1, compared to V12Rac1 alone in HCT116 colorectal
cancer cells by Western blotting analysis (Fig. 2A). A similar
stabilizing eﬀect by DNTCF4 was observed on WT Rac1
expression, indicating that increased expression is not an arti-
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Fig. 3. DNTCF4 predominantly increases nuclear V12Rac1 protein
levels. (A) HCT116 cells were transfected with FLAG-tagged V12Rac1
(2 lg) and increasing amounts of DNTCF4 (2, 4, 7 lg). Ten micro-
grams of fractionated CE and NE extracts was subjected to Western
analysis and immunoblotted with FLAG antibody to detect V12Rac1.
(B) Similar to panel (A), HCT116 cells were transfected with
equivalent amounts of HA-tagged V12Rac1PBRQ and DNTCF4
and fractionated lysates were analyzed by Western blot.
V12Rac1PBRQ was detected by an HA antibody. Both blots were
re-probed with b-actin antibody to control for equal loading of protein
fractions.
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This eﬀect was speciﬁc to DNTCF4, since co-expression of WT
TCF4, which is in the same vector backbone as DNTCF4, did
not yield a similar increase in Rac1 protein levels (Fig. 2C).
Co-expression of b-catenin, a potent activator of Wnt signal-
ing yielded slightly less V12Rac1 expression compared to
WT TCF4, likely reﬂecting the fact that these two components
act at diﬀerent levels in the Wnt pathway (Fig. 2C). We per-
formed real-time reverse-transcriptase PCR to examine the
RNA expression of the transiently transfected V12Rac1 plas-
mid in the presence of increasing amounts of DNTCF4 plas-
mid, and found no appreciable change in V12Rac1 mRNA
levels in the presence of DNTCF4 (Supplementary ﬁgure 1).
This supports that the stabilizing eﬀects by DNTCF4 are likely
post-translational. Based on these observations, we speculate
that the nuclear functions of Rac1 that lead to synergistic
induction of b-catenin/TCF4 transcription may also contribute
to a feedback loop that controls Rac1 protein expression, and
hence level of activity.
3.3. Increased expression of V12Rac1 predominantly occurs in
the nucleus
As Rac1 can localize to diﬀerent cellular compartments, we
next wished to identify whether a speciﬁc pool of Rac1 was a
target for stabilization following suppression of Wnt signaling.
HCT116 cells transfected with either V12Rac1 alone, or in the
presence of increasing amounts of DNTCF4 plasmid were
fractionated into cytoplasmic and nuclear proteins and ana-
lyzed by Western blotting. As depicted in Fig. 3A, V12Rac1
was expressed in both the cytoplasmic and nuclear fractions.
However, co-expression with DNTCF4 caused a striking in-
crease predominantly in the nuclear fraction of HCT116 trans-
fected cells. If the increased expression of Rac1 is indeed
speciﬁcally occurring in the nucleus, we speculated that block-
ing Wnt signaling with DNTCF4 should have less of an eﬀect
on PBR-mutated Rac1 levels since it has reduced nuclear local-
ization. As predicted, minimal expression of PBR-mutated
Rac1 was observed in the nuclear fraction (Fig. 3B). In agree-
ment, we observed a simultaneous increase in cytoplasmic lev-
els of PBR-mutated Rac1, reﬂecting the block in Rac1 nuclearI
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pools of Rac1 are aﬀected following suppression of b-cate-
nin/TCF-dependent transcription.
3.4. Expression of DNTCF4 results in increased stability of
V12Rac1 protein
To investigate the mechanism of increased V12Rac1 expres-
sion, we examined V12Rac1 stability. We assessed the stability
of V12Rac1 alone or with DNTCF4 co-expression in the pres-
ence of cycloheximide (CHX, 20 lM), a drug that inhibits pro-
tein synthesis. Fig. 4A shows V12Rac1 expression is
signiﬁcantly reduced upon treatment of cells with CHX (0–
12 h) compared to vehicle-treated control cells (Left panel).
Intriguingly, co-expression of DNTCF4 markedly increases
the expression level of V12Rac1, which remains elevated de-
spite CHX treatment. It is possible that the increased stability
of Rac1 in the presence of DNTCF4 in CHX treated cells was
due to an indirect modulation of another factor, since CHX is0 2 6 12 0 2 6 12
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Fig. 4. Eﬀect of DNTCF4 on V12Rac1 stability. (A) HCT116 cells co-transfe
were subsequently treated with cycloheximide (CHX, 20 lM) or vehicle (DM
were analyzed by Western blot. FLAG epitope-tagged V12Rac1 expression w
experiment for V12Rac1 protein stability in the absence (r) or presence (j
experiments. Values are expressed as the means ± S.D. *P < 0.01 compareda global protein synthesis inhibitor. Hence we took a more di-
rect approach by analyzing V12Rac1 stability by pulse-chase
analysis to conﬁrm that DNTCF4 expression regulated the sta-
bility of Rac1. In agreement with previous reports, we ob-
served V12Rac1 to be very stable, with a half-life of 12 h in
HCT116 cells (Fig. 4B) [4]. However, an increase in half-life
was observed in the presence of DNTCF4, conﬁrming that
Rac1 does get stabilized in the presence of DNTCF4.
3.5. Proteasome inhibition induces Rac1b protein accumulation
Although Rac1 expression has been demonstrated to be un-
der modulation by proteasomal degradation in human aortic
endothelial cells (HAEC) and Chinese hamster ovary cells
(CHO), whether its tumor-speciﬁc splice variant Rac1b be-
haves similarly remains unknown [3,7]. To investigate prote-
asomal degradation of Rac1b, expression of Rac1b was
examined in fractionated lysates following treatment with a
proteasomal inhibitor, MG-132. As depicted in Fig. 5A, treat-0 2 6 12 0 2 6 12
Vehicle CHX (20 μM)
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Fig. 5. Eﬀect of proteasome inhibition on Rac1b stability in colorectal
cancer cells. (A and B) HCT116 or SW480 cells transfected with
FLAG-tagged Rac1b were treated with MG-132 (10 lM) or vehicle
(negative control) for 4 h. Ten micrograms of fractionated CE and
NE lysates was analyzed by Western blot. Control lanes denote
untreated cells. Results presented are representative of three indepen-
dent experiments.
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with MG-132 resulted in signiﬁcant increase in cytoplasmic
expression of Rac1b. Intriguingly, an accompanying decrease
in the nuclear fraction of Rac1b was observed in MG-132 trea-
ted cells. Similar stabilization of cytoplasmic Rac1b was ob-
served in another well-characterized colorectal cancer cell
line, SW480 (Fig. 5B).4. Discussion
The results of this study demonstrate the signiﬁcant contri-
bution of the C-terminal region of Rac1 as a determinant of
Rac1 functions in the nucleus. Building on our previous obser-
vations of a novel cross-talk of the Rac1 GTPase with the
canonical Wnt/b-catenin signaling pathway, we identify re-
gions of Rac1 that are important for functional regulation of
Wnt signaling. We show that the NLS activity within the
Rac1 PBR is essential for mediating the synergistic activation
of transcription of Wnt target genes. In addition, we provide
evidence that a negative feedback loop may exist, whereby nu-
clear Rac1 may be targeted for degradation, since abolishing
nuclear Wnt pathway signaling by expression of DNTCF4,
leads to increased stability of V12Rac1.
Rac1 activation has been associated with several signaling
pathways that ultimately transduce signals to the nucleus to al-ter the transcription of speciﬁc target genes. Rac1 modulates
the activity of numerous transcription factors by activating
the c-Jun amino-terminal kinase (JNK) and p38 MAP kinase
pathways [12,13]. Activation of these pathways by Rac1 is be-
lieved to occur in the cytoplasm, whereby Rac1 activates spe-
ciﬁc downstream eﬀectors that perpetuate the signal to the
nucleus to alter gene transcription. However, our data reveals
that Rac1 may actually have to travel to the nucleus to
inﬂuence transcriptional activation. Mutation of the PBR
completely abolished Rac1’s synergistic eﬀects on b-catenin/
TCF-dependent transcription. Since mutating the PBR dimin-
ishes nuclear localization of Rac1, we speculate that depletion
of Rac1 in the nucleus is the reason for the lack of transcrip-
tion. Complex formation between Rac1 and b-catenin or
Dvl-3 was observed predominantly in the nucleus, providing
further evidence for Rac1 function in the nucleus.
Rac1 degradation is emerging as an important modulator of
Rac1 activity, particularly for PBR-dependent Rac1 functions
in the nucleus [3]. Replacement of the Rac1 PBR with the
RhoA PBR, which lacks a NLS, results in increased expression
of this mutant in the cytoplasm. Based on such observations, it
was postulated the Rac1 pool which travels to the nucleus is
destined for degradation. Our observations further substanti-
ate this model. Inhibition of Wnt target gene transcription
with DNTCF4, caused a dose-dependent increase in
V12Rac1 protein expression, which was more striking in the
nuclear versus cytoplasmic fraction of cells. Pulse-chase and
cycloheximide experiments clearly evidenced that the increased
expression is due to an increased stabilization of V12Rac1. It is
plausible that blocking nuclear Wnt signaling with DNTCF4
likely interferes with the signaling circuitry that ultimately tar-
gets Rac1 for degradation.
Furthermore, we provide evidence that the tumor-speciﬁc
splice variant Rac1b, is regulated by proteasomal degradation
in HCT116 cells. Treatment with a proteasome inhibitor MG-
132 resulted in the appearance of a higher molecular weight
species of Rac1b as well as increased expression of Rac1b. This
pattern of Rac1b regulation was observed in two independent
colorectal cancer cell lines, HCT116 and SW480. Both these
cell lines have constitutively active Wnt signaling due to muta-
tion in the b-catenin and APC genes, respectively. The com-
mon element in these two cell lines is an accumulation of
stabilized b-catenin and resultant increased Wnt target gene
transcription. The increased levels of cytoplasmic Rac1b in
the presence of MG132 suggest that Rac1b is under proteaso-
mal regulation. Intriguingly, a simultaneous decrease in Rac1b
levels was observed in the nuclear fraction of MG132-treated
cells. We have recently published that Rac1b is normally tar-
geted to the nucleus to function in nuclear transcriptional
events, hence augmenting Wnt pathway signaling [9]. In light
of this new data, it is temping to speculate that under circum-
stances of proteasomal inhibition, Rac1b nuclear translocation
may be prevented by as yet unknown factor(s) and/or by
favouring its retention in the cytoplasm, which would account
for the simultaneous increase in the cytoplasmic and decrease
in the nuclear fraction of Rac1b. A similar decrease in nuclear
V12Rac1 levels was observed following MG-132 treatment
(data not shown). Furthermore, since we observed an increase
in the cytoplasmic fractions of MG-132 treated cells, it is pos-
sible that nuclear Rac1/Rac1b may be exported to the cyto-
plasm to undergo proteasomal degradation. Several proteins
have been shown to undergo similar regulation. Cyclic AMP
β
Rac1
TCF
β
Rac1
Transcription of
Rac/Wnt target genes
Rac1 degradation
Cytoplasm
Nucleus
Rac1
Fig. 6. Model of Rac1 regulation by negative feedback loop during
Wnt pathway activation. The PBR of Rac1 directs cytoplasmic Rac1-
b-catenin complexes to the nucleus where they synergize to augment
Wnt target gene transcription. The protein products of one or more
Rac/Wnt target genes may negatively feedback to inhibit the activity of
nuclear Rac1, by coordinating its export back to the cytoplasm where
it is targeted for proteasomal degradation. Alternatively, Rac1
degradation may occur in the nucleus (not shown).
4856 S. Esufali et al. / FEBS Letters 581 (2007) 4850–4856response element binding protein (CREB) undergoes nuclear
export and proteasomal degradation following stimulation
with platelet derived growth factor (PDGF) [14]. b-Catenin
has been shown to transiently enter the nucleus, likely to acti-
vate target genes, and then exit to the cytoplasm where it is tar-
geted for proteasomal degradation [15].
Taken together, we propose a model whereby the PBR of
Rac1 directs Rac1-b-catenin complexes to the nucleus where
they synergize to augment Wnt target gene transcription
(Fig. 6). The activity of this nuclear pool of Rac1 may be reg-
ulated by a negative feedback loop by being exported back to
the cytoplasm where it is targeted for proteasomal degrada-
tion. Alternatively, proteasomal degradation enzymes have
also been shown to exist in the nucleus, and therefore it is pos-
sible that Rac1 degradation occurs in the nucleus as well [16].
Deactivation of Rac1 by the ubiquitin/proteasome system
could represent a decisive mechanism to turn oﬀ Rac1 GTP ef-
fects and its sustained activation in the nucleus. The cellular
signals that may target Rac1 for proteasomal degradation
are not yet known and warrant further investigation. Speciﬁ-
cally, whether and how Rac1/Rac1b is ubiquitinated following
Wnt pathway activation should be examined. Also, since the
functional consequence of DNTCF4 expression is suppression
of Wnt target gene expression, it is possible that one or more of
such target genes could be involved in mediating Rac1 degra-
dation. This would explain the increased Rac1 expression ob-
served in the presence of DNTCF4. Studies to address whether
Rac1-b-catenin signaling may cause expression of a unique
gene or subset of genes that negatively feeds back to repress
further Rac1 activity is currently being addressed in our lab.
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